secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001655759-25-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas reports Q4/FY2024 results; VERITAC-2 Phase 3 topline data expected in Q1 2025
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $1,039.4M as of Dec 31, 2024; revenue $263.4M.
- VERITAC-2 Phase 3 monotherapy topline data in ER+/HER2- mBC anticipated in 1Q25; two new Phase 3 combos planned in 2025.
- ARV-102 (LRRK2 degrader) Phase 1 in Parkinson's initiated; SAD data in healthy volunteers to be presented at AD/PD in April 2025.
- Alex Santini appointed interim Chief Commercial Officer effective January 17, 2025.
- Cash runway sufficient into 2027; VERITAC-3 (vepdegestrant+palbociclib) discontinued beyond study lead-in.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000008/0001655759-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000008/arvn-20250211.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer